share_log

Where Mineralys Therapeutics Stands With Analysts

Benzinga ·  Mar 16, 2023 08:05

Analysts have provided the following ratings for Mineralys Therapeutics (NASDAQ:MLYS) within the last quarter:

BullishSomewhat BullishIndifferentSomewhat BearishBearish
Total Ratings33000
Last 30D01000
1M Ago32000
2M Ago00000
3M Ago00000

These 6 analysts have an average price target of $36.83 versus the current price of Mineralys Therapeutics at $16.35, implying upside.

Below is a summary of how these 6 analysts rated Mineralys Therapeutics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the more negative analysts are on the stock

This current average represents a 7.93% decrease from the previous average price target of $40.00.

Stay up to date on Mineralys Therapeutics analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Analyst Ratings: What Are They?

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.

Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment